尼卡地平控制性降压对家犬脊髓血流的影响

目的　观察尼卡地平控制性降压对家犬脊髓血流的影响。方法　成年杂种犬 6只 ,体重 12 5～ 16kg ,以 2 5 %硫喷妥钠麻醉。股动脉置管监测MAP。以尼卡地平 8μg·kg 1·min 1持续静脉注射控制性降压。以激光多普勒血流仪测定脊髓血流 (SCBF)。结果　降压前MAP为 (12 5 7±10 6 )mmHg ,降压后为 (72 0± 11 2 )mmHg ,平均下降 4 2 8%。降压前SCBF为 (9 80± 1 0 5 )v ,降压后为 (8 0 4± 0 96 )v ,降低幅度为 18%。结论　尼卡地平控制性降压对SCBF影响较小 ,可安全用于脊髓手术。     

抑郁症的睡眠脑电图与人脑兴奋守恒假说

目的　探索抑郁症状与睡眠脑电图参数的相关性。方法　对 18例抑郁症和 10例正常人评定汉密尔顿抑郁评定量表 (HAMD)和检测睡眠脑电图。结果　HAMD总分与觉醒次数及REM密度分别呈显著正相关 (r分别等于 0 .4 0 8和 0 .4 4 5 ,P均 <0 .0 5 )。结论　抑郁症和正常人的白天中枢抑制与夜间中枢兴奋相关 ,从而支持人脑兴奋守恒假说。     

多巴酚丁胺负荷超声心动图及组织多普勒成像技术在诊断冠心病中的临床应用

目的探讨多巴酚丁胺负荷超声心动图(DSE)和组织多普勒成像技术(TDI)在冠心病(CHD)诊断中的应用价值,以寻求一种敏感的、无创的CHD诊断方法。方法选择胸闷或胸痛怀疑CHD患者40例,应用TDI测量静息状态(Rest)下前壁中段收缩峰值速度(Vs),以及多巴酚丁胺峰值负荷状态(Peak)下前壁中段Vs,同时测量静息心率和负荷心率;所有入选对象均进行冠脉造影,并根据左前降支狭窄程度是否大于等于50%分为左前降支狭窄组(LST组)与左前降支非狭窄组(non-LST组)。分别比较Rest和Peak前壁中段LST组与non-LST组平均Vs差别等。结果Rest前壁中段LST组与non-LST组Vs差别无显著性意义;但Peak前壁中段LST组与non-LST组差别有显著性意义。结论DSE结合TDI是诊断冠心病有价值的定量分析方法。DSE在诊断CHD时的敏感性、准确性明显优于静息状态超声心动图。     

脊神经节神经元周围突至肾及体壁的分支投射

实验将快蓝(FB)和核黄(NY)分别注入大鼠左肾纤维膜下及左体壁神经干内,结果在荧光镜下发现左T_(9-13),L1脊神经后根节(DRG)内存在双标记细胞,提示大鼠T_(9-13),L1段DRG内的部分神经元的周围突分支支配肾及体壁,为肾绞痛所致牵涉痛的解释,提供了神经解剖学基础。     

硝基化合物还原、氢化的研究 Ⅳ.用Fe~(3+)催化转移氢化3,3′-二硝基-4,4′-二氨基二苯醚

以Fe~(3+)代替Pd-C和Raney Ni为催化剂、水合肼为供氢体、3,3′-二硝基-4,4′-二氨基二苯醚为受氢体、甲醇为溶剂,进行催化转移氢化反应,产物3,3′,4,4′-四氨基二苯醚(TADPO)质量好,得率可达80%。此外,还对反应温度、时间、以及水合肼、催化剂、溶剂用量,水合肼浓度、催化剂重复使用等影响因素进行了研究,获得了较佳工艺条件。本法制得的TADPO与均苯四甲酸二酐缩聚可制得性能良好的聚眯唑吡咙。     

相对湿度对空调环境至适温度影响的研究

本文研究空调室内相同温度（夏季：２４℃，２８℃：冬季：１９℃；２２℃）条件下相对湿度（分别为３０～７０％；８５～９５％）对至适温度的影响。以健康成年人为研究对象，以体温、皮温、皮温差、温热感和舒适感为观察指标。结果表明：空调室内气温相同时，皮温差、温热感、舒适感均随气湿不同而出现差异。夏季空调温度为２８℃、气湿为８５～９５％时，皮温差（２．１℃）已超出生理至适范围，温热感（１２．５％）和舒适感（０％）也随湿度增高而下降（Ｐ＜０．０１）。提出在制订空调至适温度卫生标准时，应考虑空气湿度对至适温度的影响。     

Missense mutations and evolutionary conserved amino acids at the human hypoxanthine phosphoribosyl-transferase locus.

Molecular characterization of in vivo mutation at the human hypoxanthine phosphoribosyltransferase (hprt) locus has revealed a broad spectrum of mutation, both with regard to germ-line mutation in Lesch-Nyhan and gout patients, and somatic mutation in 6-thioguanine resistant T-lymphocytes from healthy individuals. The pattern of missense mutation shows a non-random distribution with a preferential location to codons for amino acids which are identical in human and the two parasites Schistosoma mansoni and Plasmodium falciparum. Although these 'evolutionary conserved' amino acids account for only 32% of the amino acids in the human hprt protein, they are involved in 76% of the missense mutations at the hprt locus in human T-lymphocytes, 67% in Lesch-Nyhan patients (with severe hprt-deficiency), but only 43% in gout patients (with partial hprt deficiency). This observation supports the notion that evolutionary conserved amino acids constitute functionally important sites in the hprt enzyme, and missense mutations affecting these amino acids will often lead to complete loss of enzyme activity. Substitutions of 'non-conserved' amino acids cause less severe hprt-deficiency (as seen in the gout patients), or may even escape clinical diagnosis. These considerations are important for the understanding of structure-activity relationships in the hprt protein, possible differences between hprt mutational spectra in germ-line and somatic cells, and the mutational spectra induced by specific exogeneous mutagens.     

VEGF-C和VEGF-D蛋白表达在胰腺癌淋巴转移中的意义

目的探讨胰腺癌中VEGF-C、VEGF-D蛋白表达与淋巴结转移之间的相关关系,阐明癌周淋巴管增生在胰腺癌淋巴转移中的作用及意义。方法免疫组化检测30例胰腺癌组织中VEGF-C、VEGF-D的表达及其与临床病理、淋巴结转移的关系。结果胰腺癌VEGF-C、VEGF-D蛋白表达阳性率分别为73%(22/30)、57%(17/30),肿瘤周边部位显著高于肿瘤中心部位,其表达与肿瘤的部位、分化程度、组织学类型无关,与肿瘤的TNM分期有关,Ⅲ~Ⅳ期显著高于Ⅰ~Ⅱ期。在VEGF-C、VEGF-D蛋白阳性组,淋巴结转移均显著增多。结论VEGF-C和VEGF-D与诱导胰腺癌淋巴管生成,促进肿瘤细胞淋巴道转移有关。     

Efficacy of lumiracoxib in relieving pain associated with knee osteoarthritis: a 6‐week,randomized, double‐blind,parallel‐group study

Aim: The aim of the current study was to assess the efficacy, safety, and tolerability of lumiracoxib 200 mg once daily (o.d.) in relieving osteoarthritis (OA) knee pain in patients in China, Taiwan, and South Korea. Methods: Patients of either sex (aged ≥ 18 years) with symptomatic, primary OA of the knee for ≥ 3 months were eligible for inclusion if they had OA pain intensity of ≥ 40 mm (100 mm visual analogue scale [VAS]) in the target knee joint during the previous 24 h. Patients were required to undergo regular non‐steroidal anti‐inflammatory drug therapy for ≥ 6 weeks. After 3–7 days of screening, patients were randomized (1 : 1) to receive either lumiracoxib 200 mg o.d. or celecoxib 200 mg o.d. The primary efficacy comparison between the study groups was overall OA pain intensity (VAS) in the target knee after 6 weeks of treatment. Results: The mean overall OA pain intensity (VAS) in the target knee after 6 weeks decreased from 60.6 mm to 35.7 mm and 60.5 mm to 36.1 mm in the lumiracoxib and celecoxib groups, respectively. Both study groups showed similar results in terms of improvement in both patient's and physician's global assessment of disease activity and functional health status. The percentage of adverse events (AEs) in the lumiracoxib and celecoxib groups (40.3% and 37.9%, respectively) was similar, as was the proportion of treatment‐related AEs (21.0% and 18.2%, respectively). Conclusions: Lumiracoxib 200 mg o.d. provided effective and well‐tolerated pain relief similar to that achieved with celecoxib 200 mg o.d. in knee OA patients.